- About CAA
- Asbestos Related Disease
- What Is Asbestos?
- Asbestos Legacy/Statistics
- Asbestos in Schools
- What is Pleural Plaque & Benign Pleural Disease?
- What is Asbestosis?
- Self-management Toolkit
- What is Asbestos-related Lung Cancer?
- What is Mesothelioma?
- Treatment of Mesothelioma
- Information for Those Diagnosed
- Information for Families
- Power of Attorney, Appointees & Representatives
- Information for the Medical Profession
- Managing Your Asbestos Related Condition – Video
- Compensation & Benefits
- Mesothelioma Compensation
- Asbestos- related Industrial Injuries Disablement Benefit & State (government) Compensation
- The Pneumoconiosis etc. (Workers Compensation) Act 1979
- Diffuse Mesothelioma Scheme 2008
- Diffuse Mesothelioma Payment Scheme (DMPS) 2014
- State (government) Benefits
- Civil Compensation
- Procurator Fiscal & Coroner – Posthumous Claims
- Wills, Probate and Inheritance
- Pleural Plaques Compensation
- Armed Forces Compensation
- Expatriates & Asbestos – Related Benefits & Compensation
- Help Us
- Support Us / Donate
- Donate with a Fundraising Event
- Make a one off Donation in Memory
- Create a page in Memory of a Loved One
- Donate by Cash, Cheque, or Card
- Donate Regularly/Direct Debit
- Donate by Text Message
- Donate by Legacy/Leave a Gift in your Will
- Donate by Payroll
- Gift Aid Declaration, Sponsorship & Standing Order Forms
- Membership of CAA
The standard treatment for mesothelioma is often referred to as best supportive care (BSC) or active symptom control (ASC), to highlight the fact that the doctors and nurses will be seeking actively to identify and relieve symptoms of the disease. Increasingly chemotherapy is regarded as part of standard treatment for patients fit enough to receive it.
In the earlier stages of pleural mesothelioma there is often a recurrent pleural effusion which causes breathlessness. This is dealt with by pleurodesis which means inducing adhesions between the lung and chest wall. This closes off the pleural space so the effusion cannot reform. It is usually performed by putting sterile talc into the chest through the tube used to drain the fluid.
Chest pain is another common problem. Painkilling drugs are usually effective. If pain remains severe despite drugs a minor surgical procedure called cordotomy can be effective. This is done under local anaesthesia and the aim is to disable the pain carrying nerves in the spinal cord. Various other symptoms including sweating, loss of appetite and weight may also be helped by medication.
Surgery for Mesothelioma
In some cases it is helpful to remove the pleura from around the lung to help the lung to expand better, a procedure known as pleurectomy (sometimes referred to as decortication). This procedure cannot eliminate the mesothelioma completely and it grows back again.
In highly selected cases with early stage disease more radical surgery called extra-pleural pneumonectomy can be considered. The surgeon attempts to remove the mesothelioma completely, which involves taking out the whole lung and parts of neighbouring structures ie the diaphragm which separates the lung from the abdomen and the pericardium, the covering of the heart. Some experienced clinicians report that a few patients enjoy long term survival after this procedure. However, the average survival is no better for patients subjected to radical surgery than for patients treated with chemotherapy.
Radiotherapy for Mesothelioma
Some doctors recommend radiotherapy to the chest wall at the sites of chest drain insertion or a biopsy in order to prevent the mesothelioma growing through the skin. There is some uncertainty as to the effectiveness of this treatment and some doctors do not believe it is worthwhile.
There are two main uses of radiotherapy to treat symptoms. One is to treat a chest wall tumour which is forming a lump beneath the skin and which is causing discomfort or pain. Radiotherapy can shrink the lump and alleviate pain. The other is to relieve deeper seated pain which is not responding well to pain relieving drug therapy.
Chemotherapy for Mesothelioma
Chemotherapy can prolong survival in patients with mesothelioma. The average gain is around 2 to 3 months. This may not sound very much but the average represents some patients whose mesotheliomas do not respond to therapy who may not live any longer than they would have done without chemotherapy and others whose mesotheliomas respond well and whose survival gain is more than the average of three months. As yet there is no way to predict before treatment starts which mesotheliomas will respond well and which will not.
The chemotherapy of first choice is pemetrexed (trade name Alimta) in combination with either cisplatin or carboplatin. The drugs are given through a drip in an arm vein. The treatment is given on an out-patient basis and does not require hospitalization. Usually 4 to 6 cycles are administered at 3 week intervals.
A CT scan is performed after every 2 or 3 cycles to assess progress. If the mesothelioma has stayed the same size or shrunk treatment is continued but if the tumour has grown treatment is discontinued. The treatment is generally well tolerated and can help symptoms of the illness as well as prolong survival. However, some patients do not tolerate it well in which case it is discontinued. Side effects are usually not severe but can include sore mouth and eyes, tiredness and sickness. There is usually little, if any, hair loss.
Another type of chemotherapy used is vinorelbine (trade name Navelbine). This can also relieve symptoms of mesothelioma and it can probably prolong life by an average of 2 months, although the evidence for prolongation of life is less strong than for pemetrexed. This drug has the advantage of being available in tablet form so the treatment can be given without the need for hospital admission. It is usually well tolerated without serious side effects. Vinorelbine can be used as second line therapy in patients who have previously received pemetrexed.
There is a recently opened randomised trial known as MARS-2 which aims to assess the value of major surgery called extended pleurectomy and decortication, ie stripping of the parietal pleura lining the ribcage, the visceral pleura from around the lung and resection of the diaphragm and pericardium if they are involved by tumour. Patients are randomly allocated to received standard chemotherapy alone or chemotherapy plus surgery.
A recent randomised trial showed significant prolongation of survival by a median of 2.7 months with the addition of bevacizumab to standard chemotherapy with pemetrexed and cisplatin. Bevacizumab is expensive and unlikely to be approved by NICE for the treatment of mesothelioma.
Various new biological agents are under investigation. There have been promising response rates in early trials with ADI – PEG and with Pembrolizumab. A randomised trial comparing standard chemotherapy with standard chemotherapy plus ADI – PEG known as the TRAP trial is under way.
The emergence of new drugs gives real hope for improvement in the outlook in the foreseeable future.
Bart’s Mesothelioma Research
More information on clinical trials for mesothelioma is available from the UK Clinical Trial Gateway:
Reviewed by Dr Robin Rudd: February 2016
Due for review: February 2017